PDF(Pubmed)
Abstract：
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to the lack of specific therapeutic targets, treatment options are limited, and the recurrence and metastasis rate is high, the overall survival of patients is poor. However, with the discovery of some new targets and the corresponding immune regulation after targeting these targets, TNBC has a new hope in treatment. The peptide has a simple structure, strong binding affinity, and high stability, and has great potential in targeted therapy and immune regulation against TNBC. This review will discuss how single peptides and peptide combinations target triple-negative breast cancer to exert immunomodulatory effects. Among them, single peptides target specific receptors on TNBC cells, act as decoys to target key ligands in the regulatory pathway, and target TME-related cells. The combinations of peptides work in the form of cancer vaccines, engineered exosomes, microRNAs and other immune-related molecular pathways, immune checkpoint inhibitors, chimeric antigen receptor T cells, and drug-peptide conjugates. This article is mainly dedicated to exploring new treatment methods for TNBC to improve the curative effect and prolong the survival time of patients.
摘要：
三阴性乳腺癌（TNBC）是最具侵袭性的乳腺癌亚型。由于缺乏特定的治疗靶点，治疗选择有限，复发和转移率高，患者的总体生存率较差。然而,随着一些新的靶标的发现以及靶向这些靶标后相应的免疫调节，TNBC在治疗上有了新的希望。该肽具有简单的结构，强结合亲和力，和高稳定性，在针对TNBC的靶向治疗和免疫调节方面具有巨大潜力。本文将讨论单肽和肽组合如何靶向三阴性乳腺癌发挥免疫调节作用。其中,单肽靶向TNBC细胞上的特异性受体，作为诱饵靶向调控途径中的关键配体，并靶向TME相关细胞。肽的组合以癌症疫苗的形式起作用，工程外泌体，microRNAs和其他免疫相关分子通路，免疫检查点抑制剂，嵌合抗原受体T细胞，和药物-肽缀合物。本文主要致力于探索TNBC治疗的新方法,以提高疗效,延长患者生存时间。
